How does Vitrakvi (larotrectinib) work in the body?
Vitrakvi (larotrectinib) is a targeted cancer medicine used to treat tumors that have certain gene fusions involving the NTRK genes (for example, NTRK1, NTRK2, or NTRK3). It works by blocking the abnormal NTRK signaling that drives tumor growth, which slows or stops cancer cell proliferation. [1]
What does larotrectinib inhibit exactly?
Larotrectinib is designed to inhibit TRK (tropomyosin receptor kinase) proteins produced from NTRK gene fusions. When those fusions are present, TRK signaling can be “turned on” in a way that supports tumor survival and growth. Larotrectinib prevents that signaling, which is the core mechanism behind its antitumor effect. [1]
What’s the clinical rationale behind blocking NTRK/TRK?
Because larotrectinib is aimed at the tumor’s underlying driver alteration (an NTRK fusion), its activity depends on whether the patient’s tumor contains an NTRK gene fusion. When the fusion is present, blocking TRK signaling can reduce growth of the cancer cells that rely on that pathway. [1]
Where can I verify the mechanism wording and labeling details?
For the exact “Mechanism of Action” language and any related labeling context (such as indications tied to NTRK gene fusion status), check the DailyMed label for Vitrakvi (larotrectinib). [1]
Source
[1] DailyMed. “VITRAKVI (larotrectinib).” https://dailymed.nlm.nih.gov/